written on 25.03.2014
Tags:
,

Even at a discount, Sanofi's pricey cancer drug Zaltrap can't win at NICE

TAGS: ,

The U.K.'s National Institute for Health and Care Excellence has spurned Sanofi's colon cancer treatment Zaltrap once again. And this time, the decision is final. The cost-effectiveness agency dismissed the French company's appeal, despite the offer of a discount.

Latest Report